- Q1 2024 Calliditas Therapeutics AB Earnings Call TranscriptMay 23, 2024kr122.2 (+7.19%)Earnings
- Q4 2023 Calliditas Therapeutics AB Earnings Call TranscriptFeb 21, 2024kr108.3 (+1.31%)Earnings
- Q3 2023 Calliditas Therapeutics AB Earnings Call TranscriptNov 07, 2023kr87.6 (-5.40%)Earnings
- Q2 2023 Calliditas Therapeutics AB Earnings Call TranscriptAug 17, 2023kr86.25 (-13.92%)Earnings
- Q1 2023 Calliditas Therapeutics AB Earnings Call TranscriptMay 16, 2023kr107.2 (-18.42%)Earnings
- Calliditas Therapeutics AB Nefigard Topline Data Presentation TranscriptMar 13, 2023
- Q4 2022 Calliditas Therapeutics AB Earnings Call TranscriptFeb 23, 2023kr107 (+16.49%)Earnings
- Calliditas Therapeutics AB Fireside Chat with Everest Medicines Ltd TranscriptDec 14, 2022
- Q3 2022 Calliditas Therapeutics AB Earnings Call TranscriptNov 14, 2022kr78.9 (+0.96%)Earnings
- Calliditas Therapeutics AB KOL Webinar TranscriptNov 08, 2022
- Q2 2022 Calliditas Therapeutics AB Earnings Call TranscriptAug 18, 2022kr91.8 (-15.55%)Earnings
- Q1 2022 Calliditas Therapeutics AB Earnings Call TranscriptMay 18, 2022kr79.6 (+7.49%)Earnings
- Q4 2021 Calliditas Therapeutics AB Earnings Call TranscriptFeb 24, 2022kr81.3 (-6.12%)Earnings
- Calliditas Therapeutics AB -FDA Approval of TARPEYO to Reduce Proteinuria in IgA Nephropathy TranscriptDec 16, 2021
- Q3 2021 Calliditas Therapeutics AB Earnings Call TranscriptNov 18, 2021kr80 (+8.25%)Earnings
- Q2 2021 Calliditas Therapeutics AB Earnings Call TranscriptAug 19, 2021kr96.5 (-1.63%)Earnings
- Q1 2021 Calliditas Therapeutics AB Earnings Call TranscriptMay 18, 2021kr120.8 (+0.50%)Earnings
- Calliditas Therapeutics AB (publ) - Special Call TranscriptMar 10, 2021
- Q4 2020 Calliditas Therapeutics AB Earnings Call TranscriptFeb 18, 2021kr128.6 (-3.02%)Earnings
- Calliditas Therapeutics AB Corporate Analyst Meeting TranscriptJan 20, 2021
- Q3 2020 Calliditas Therapeutics AB Earnings Call TranscriptNov 12, 2020kr145.8 (-4.58%)Earnings
- Calliditas Therapeutics AB (publ) - Special Call TranscriptNov 09, 2020
- Q2 2020 Calliditas Therapeutics AB Earnings Call TranscriptAug 13, 2020kr103 (+2.39%)Earnings
- Q1 2020 Calliditas Therapeutics AB Earnings Call TranscriptMay 14, 2020kr92.5 (-9.49%)Earnings
Q1 2023 Calliditas Therapeutics AB Earnings Call Transcript
()-
Thank you very much, and welcome, everybody, to this Q1 2023 report. With me today, I have Fredrik Johansson, Chief Financial Officer; Richard Philipson, our Chief Medical Officer; and Andrew Udell, President of North America.
Next slide, please. I'd like to just draw your attention to the disclaimer page. It relates to any forward-looking statements, and I would like to refer you to the company's reports and other filings, including those which contain risk factors and other relevant information.
Next page, please. So some highlights for Q1. In February, we received conditional marketing authorization from the MHRA for Kinpeygo, which thus became the first-ever approved treatment for IgA nephropathy in the U.K. In March, we obviously had our main event for the quarter. We read out top line data from the global placebo-controlled randomized Phase III study known as NefIgArd, which met its primary endpoint of kidney function expressed as eGFR. The trial was very successful and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)